Bristol Myers surges after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter revenue at ...

The Bristol Myers Squibb medicine is said relieve symptoms without causing some of the harsh side effects of drugs already in use. Meanwhile, thousands of patients allege in a lawsuit that drugs used ...

Data through the week points to a still-resilient economy overall, leaving traders uncertain about the Fed’s next move.

Stock futures were modestly higher ahead of the release of the Federal Reserve's preferred measures of inflation, as major ...

KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually. The drug represents a new way to treat adults with schizophrenia.

Jeffrey Rubin, the president and director of research at Westport, Conn.-based Birinyi Associates - who now owns the firm following the death of the legendary Laszlo Birinyi - is among those who is ...

There's a newly approved drug for schizophrenia from Bristol Myers Squibb.

Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The ...

As of now, Bristol Myers Squibb has registered a Year-to-Date (YTD) stock performance of +1.48%. This figure starkly contrasts with the S&P 500’s impressive YTD performance of +20.45%. While BMY’s ...

With U.S. stock markets set to open in two hours, Bristol Myers Squibb Co. (BMY) was up 4.6% in pre-market trading, and Las Vegas Sands Corp. (LVS) was up 4.4%. Back To Top ...

Inflation moderating towards the central bank's 2% target gave the Fed enough room to commence its policy easing cycle with a 50 basis point rate cut last week.

Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...